Pangaea Oncology, S.A. Share Price

Equities

PANG

ES0105221008

Biotechnology & Medical Research

Delayed BME 15:00:25 26/04/2024 BST 5-day change 1st Jan Change
1.71 EUR 0.00% Intraday chart for Pangaea Oncology, S.A. -3.93% -7.07%

Financials

Sales 2023 * 10.8M 11.57M 924M Sales 2024 * 16.2M 17.36M 1.39B Capitalization 50.35M 53.95M 4.31B
Net income 2023 * - 0 0 Net income 2024 * - EV / Sales 2023 * 4.78 x
Net Debt 2023 * 1.3M 1.39M 111M Net Debt 2024 * 1.9M 2.04M 163M EV / Sales 2024 * 3.23 x
P/E ratio 2023 *
-85.5 x
P/E ratio 2024 *
-
Employees 58
Yield 2023 *
-
Yield 2024 *
-
Free-Float 21.08%
More Fundamentals * Assessed data
Dynamic Chart
1 week-3.93%
Current month-8.06%
1 month-8.06%
3 months-2.84%
6 months-16.99%
Current year-7.07%
More quotes
1 week
1.71
Extreme 1.71
1.78
1 month
1.71
Extreme 1.71
1.86
Current year
1.71
Extreme 1.71
1.91
1 year
1.68
Extreme 1.68
2.42
3 years
1.31
Extreme 1.31
2.42
5 years
0.97
Extreme 0.97
2.70
10 years
0.97
Extreme 0.97
3.50
More quotes
Managers TitleAgeSince
Founder - 31/12/06
Founder - 31/12/06
Founder - 31/12/06
Members of the board TitleAgeSince
Founder - 31/12/06
Founder - 31/12/06
Founder - 31/12/06
More insiders
Date Price Change Volume
26/04/24 1.71 0.00% 0
25/04/24 1.71 0.00% 2,800
24/04/24 1.71 -3.93% 3,911
23/04/24 1.78 +2.89% 1,384
22/04/24 1.73 -2.81% 1,488

Delayed Quote BME, April 26, 2024 at 03:00 pm

More quotes
Pangaea Oncology SA is a Spain-based company primarily engaged in the biotechnology sector. The Company focuses on the development of oncology treatments. The Company’s activities are divided into two business lines: Clinical care in the Dr. Rosell Oncology Institute (IOR) and Molecular diagnosis (Dx). The IOR division offers personalized medical services related to oncology area, such as diagnosis, laboratory testing and treatment, in a chain of hospitals in Catalonia, Spain. The Dx division is responsible for the development of diagnostic and in-vitro services, biomarkers, as well as targeted drugs for patients and pharmaceutical companies. Its diagnostic models include Liquid Biopsy and Multiplexing.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Annual profits - Rate of surprise